|Table of Contents|

New Research Progress on Anti-Inflammatory Mechanism of Arctigenin(PDF)

《南京师大学报(自然科学版)》[ISSN:1001-4616/CN:32-1239/N]

Issue:
2017年02期
Page:
83-
Research Field:
·生命科学·
Publishing date:

Info

Title:
New Research Progress on Anti-Inflammatory Mechanism of Arctigenin
Author(s):
Kang Jingjing1Liu Xiaoning1Yin Zhimin2
(1.Department of Biochemistry,School of Medicine,Huanghe College of Science and Technology,Zhengzhou 450063,China)(2.School of Life Sciences,Nanjing Normal University,Jiangsu Province Key Laboratory for Molecularand Medicine Biotechnology,Nanjing 210023,China)
Keywords:
Arctigeninanti-inflammatory mechanismsinflammatory mediator
PACS:
R285.5
DOI:
10.3969/j.issn.1001-4616.2017.02.014
Abstract:
Arctigenin,a bioactive constituent from dried seeds of Arctium lappa L. which has extensive pharmacological action,was found to exhibit satisfactory therapeutic effects in inflammatory diseases. Here,we summarize the research progress on anti-inflammatory mechanism of arctigenin,and analyze the research direction in the future,which can provide a reference for the research and development of anti-inflammatory drugs based on arctigenin.

References:

[1] 王潞,赵烽,刘珂. 牛蒡子苷及牛蒡子苷元的药理作用研究进展[J]. 中草药,2008,39(3):467-470.
[2]蔡恩博,王瑞卿,刘德民,等. 牛蒡子苷元现代药理作用研究进展[J]. 世界科学技术:中医药现代化,2016,18(1):130-134.
[3]PASPARAKIS M,HAASE I,NESTLE F O. Mechanisms regulating skin immunity and inflammation[J]. Nature reviews immunology,2014,14(5):289-301.
[4]HUANG T C,TSAI S S,LIU L F,et al. Effect of Arctium lappa L. in the dextran sulfate sodium colitismousemodel[J]. World J Gastroenterol,2010(16):4 193-4 199.
[5]XIN W,YAN Y,YANNONG D,et al. Arctigenin but not arctiin acts as the major effective constituent of Arctium lappa L. fruit for attenuating colonic inflammatory response induced by dextran sulfate sodium in mice[J]. International immunopharmacology,2014,(23):505-515.
[6]SUPRIYA R H,IN A L,WAN G,et al. Arctigenin ameliorates inflammation in vitro and in vivo by inhibiting the PI3K/AKT pathway and polarizing M1 macrophages to M2-like macrophages[J]. European journal of pharmacology,2013(708):21-29.
[7]SHI X,SUN H,ZHOU D,et al. Arctigenin attenuates lipopolysaccharide-induced acute lung injury in rats.[J]. Inflammation,2014,38(2):623-631.
[8]ZHANG W Z,JIANG Z K,HE B X,et al. Arctigenin protects against lipopolysaccharide-induced pulmonary oxidative stress and inflammation in a mouse model via suppression of MAPK,HO-1,and iNOS signaling[J]. Inflammation,2015,38(4):1 406-1 414.
[9]FAN T,JIANG W L,ZHU J,et al. Arctigenin protects focal cerebral ischemia-reperfusion rats through inhibiting neuroinflammation[J]. Biological and pharmaceutical bulletin,2012,35(11):2 004-2 009.
[10]ZHANG R,LI W,ZHANG Z,et al. Arctigenin regulates Th1 and Th17 differentiation and ameliorates experimental autoimmune encephalomyelitis(THER7P.958)[J]. The journal of immunology,2015(194):25-29.
[11]WEN L,ZHIHUI Z,KAI Z,et al. Arctigenin suppress Th17 cells and ameliorates experimental autoimmune encephalomyelitis through AMPK and PPAR-γ/ROR-γt signaling[J]. Molecular neurobiology,2016,8(53):1-11.
[12]SONG J,LI N,XIA Y,et al. Arctigenin treatment protects against brain damage through an anti-inflammatory and anti-apoptotic mechanism after needle insertion[J]. Frontiers in pharmacology,2016(7):1-16.
[13]SONG J,LI N,XIA Y,et al. Arctigenin confers neuroprotection against mechanical trauma injury in human neuroblastoma SH-SY5Y cells by regulating miRNA-16 and miRNA-199a expression to alleviate inflammation[J]. Journal of molecular neuroscience Mn,2016(60):115-129.
[14]KANG J,ZHANG Y,CAO X,et al. Lycorine inhibits lipopolysaccharide-induced iNOS and COX-2 up-regulation in RAW264.7 cells through suppressing P38 and STATs activation and increases the survival rate of mice after LPS challenge[J]. International immunopharmacology,2012,12(1):249-256.
[15]XIONG H,CHENG Y,ZHANG X,et al. Effects of taraxasterol on iNOS and COX-2 expression in LPS-induced RAW264.7 macrophages[J]. Journal of ethnopharmacology,2014,155(1):753-757.
[16]KOU X,QI S,DAI W,et al. Arctigenin inhibits lipopolysaccharide-induced iNOS expression in RAW264.7 cells through suppressing JAK-STAT signal pathway.[J]. International immunopharmacology,2011,11(8):1 095-1 102.
[17]ZHAO F,WANG L,LIU K. In vitro,anti-inflammatory effects of arctigenin,a lignan from Arctium lappa L. through inhibition on iNOS pathway[J]. Journal of ethnopharmacology,2009,122(3):457-462.
[18]YAO X,LI G,Lü C,et al. Arctigenin promotes degradation of inducible nitric oxide synthase through CHIP-associated proteasome pathway and suppresses its enzyme activity[J]. International immunopharmacology,2012,14(2):138-144.
[19]陈婧,方建国,吴方建,等. 鱼腥草抗炎药理作用机制的研究进展[J]. 中草药,2014,45(2):284-289.
[20]SUN C H,LAI X Q,ZHANG L,et al. Inhibitory effect of arctigenin on lymphocyte activation stimulated with PMA/ionomycin[J]. Acta pharmaceutica sinica,2014,49(4):482-489.
[21]ZHONG W,CUI Y,YU Q,et al. Modulation of LPS-stimulated pulmonary inflammation by borneol in murine acute lung injury model[J]. Inflammation,2014,37(4):1 148-1 157.
[22]JIANG L,XU F,HE W,et al. CD200Fc reduces TLR4-mediated inflammatory responses in LPS-induced rat primary microglial cells via inhibition of the NF-κB pathway[J]. Inflammation research,2016,65(7):1-12.
[23]CH O M K,PARK J W,JANG Y P,et al. Lipopolys accharide-inducible nitric oxide synth as eex pression by dib enzylbut yrolactone lignans through inhibition of I-κBα phos phorylation and of p65 nuclear translocation in macrophages[J]. Int Immunopharmacol,2002,67(6):1 738-1 745.
[24]CH O M K,JIANG Y P,KIM Y C,et al. Arctigenin,a phenylpropanoid diben zylbutyrolactone lignan,inhibits MAP kinases and AP-1 activation via potent MKK inhibition:the role in TNF-alph a inhibition[J]. Int Immunopharma Col,2004,4(10/11):1 419-1 429.
[25]KANG H S,JI Y L,CHANG J K. Anti-inflammatory activity of arctigenin from Forsythiae Fructus[J]. Journal of ethnopharmacology,2008,116(2):305-312.
[26]陈世宣,冯伟,周一心,等. 牛蒡子苷元对关节软骨细胞增殖及Ⅱ型胶原表达的影响[J]. 上海中医药杂志,2015(7):69-71.
[27]JI Y L,CHANG J K. Arctigenin,a phenylpropanoid dibenzylbutyrolactone lignan,inhibits typeⅠ-Ⅳ allergic inflammation and pro-inflammatory enzymes[J]. Archives of pharmacal research,2010,33(6):947-957.
[28]SIAMAK M K M D,WERTH V P. Prevention and treatment of systemic glucocorticoid side effects[J]. International journal of dermatology,2010,49(3):239-248.
[29]ISHIZAKI M,MUROMOTO R,AKIMOTO T,et al. Tyk2 is a therapeutic target for psoriasis-like skin inflammation.[J]. International immunology,2014,26(5):257-267.

Memo

Memo:
-
Last Update: 2017-06-30